Svante Almkvist Appointed Chairman of the Board at AAX Biotech

AAX Biotech announces the appointment of Svante Almkvist to Chairman of the Board of Directors, succeeding Daniel X Johansson. This transition is part of our ongoing strategy to harness Almkvist's extensive experience and strategic insight in guiding AAX Biotech's leadership in the development of innovative antibody therapeutics.

We acknowledge Daniel X Johansson's significant contributions as Chairman and express our appreciation for his leadership. Daniel X Johansson will remain on the Board of Directors and will continue to provide critical insights in the organization, while focusing on Research & Development in his role as Chief Scientific Officer of the company.

Drawing upon Svante Almkvist’s extensive background in biopharmaceutical development and manufacturing, alongside his entrepreneurial experience, his appointment promises invaluable perspectives. With his proven expertise, we anticipate his leadership will play a pivotal role in AAX Biotech’s growth. The AAX Biotech team looks forward to Svante Almkvist's leadership in his new role as Chairman, confident in the contributions he will make towards our strategic goals and mission.